Literature DB >> 9624507

In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

P M Roblin1, M R Hammerschlag.   

Abstract

The in vitro activities of HMR 3647, roxithromycin, erythromycin, and azithromycin against 19 strains of Chlamydia pneumoniae were tested. The MIC at which 90% of the isolates are inhibited and the minimum bactericidal concentration at which 90% of the isolates are killed of HMR 3647 were 0.25 microgram/ml (range, 0.015 to 2 micrograms/ml). Nine recently obtained clinical isolates from children with pneumonia were more susceptible (MICs, 0.015 to 0.0625 microgram/ml) than older strains that had been passaged more extensively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624507      PMCID: PMC105635     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  P M Roblin; W Dumornay; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

2.  In-vitro activity of ketolides against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; M D Aydin; J F Chantot; C Bébéar
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

3.  In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

Authors:  C Jamjian; D J Biedenbach; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Antimicrobial activity of RU-66647, a new ketolide.

Authors:  R N Jones; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  1997 Jan-Feb       Impact factor: 2.803

7.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

  7 in total
  27 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

Authors:  S Strigl; P M Roblin; T Reznik; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 3.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.

Authors:  Jun-Ichi Kadota; Yuji Ishimatsu; Tetsuji Iwashita; Yuichi Matsubara; Kazunori Tomono; Masao Tateno; Roza Ishihara; Claudette Muller-Serieys; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Authors:  M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

7.  Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Authors:  C Muller-Serieys; P Soler; C Cantalloube; F Lemaitre; H P Gia; F Brunner; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Fungal endophytes of turmeric (Curcuma longa L.) and their biocontrol potential against pathogens Pythium aphanidermatum and Rhizoctonia solani.

Authors:  G Vinayarani; H S Prakash
Journal:  World J Microbiol Biotechnol       Date:  2018-03-14       Impact factor: 3.312

9.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 10.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.